Enzalutamide, an AR antagonist that is commonly used in the treatment of prostate cancer, has also shown antitumor effects in TNBC because 30% of TNBC patients demonstrate AR‐positive disease.103, 104, 105. This evidence concerns the gene AR and prostate cancer.